Breakthrough Discovery Could Make Pancreatic Cancer Respond to Chemo Again

A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.

AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress

Shares of AIM ImmunoTech Inc. (NYSE American: AIM) rocketed higher Wednesday, closing at $1.02, up 31 cents or 43.66%, on extraordinarily heavy trading volume exceeding 183 million shares as investors ...

Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and ANN 2026

DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic ...
News-Press NOW

Virta Health’s Nutrition Therapy Extends Survival by 34% in Stage IV Pancreatic Cancer Patients, New Clinical Trial Shows

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II ...

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.
Hosted on MSN

New blood markers may spot early-onset pancreatic cancer before symptoms hit

Pancreatic ductal adenocarcinoma is one of the most lethal cancers, in large part because it usually stays hidden until it has already spread. Survival curves change dramatically when tumors are ...
Nasdaq

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite BioPharma CANF shares soared 20.4% on Wednesday after the company reported positive top-line results from a mid-stage study of its investigational candidate, namodenoson, in patients with ...